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Abstract
Introduction: In patients with ventilator-associated pneumonia (VAP), administration of an appropriate empirical
antimicrobial treatment is associated with improved outcomes, leading to the prescription of broad-spectrum
antibiotics, including a drug active against methicillin resistant Staphylococcus aureus (MRSA). In order to avoid the
overuse of antibiotics, the present study aimed to evaluate the technical characteristics of a rapid diagnostic test
(Cepheid Xpert assay) in patients with suspected VAP.
Methods: From June 2011 to June 2012, in patients with suspected VAP, a sample from the bronchialalveolar
lavage (BAL) or miniBAL was tested in a point-of-care laboratory for a rapid diagnostic test of methicillin
susceptible Staphylococcus aureus (MSSA) and MRSA. Then, the result was compared to the quantitative culture
with a threshold at 104 colony-forming units per milliliter for bronchoalveolar lavage and 103 colony-forming units
per milliliter for minibronchoalveolar lavage. The study was performed in three intensive care units at two
institutions.
Results: Four hundred, twenty-two samples from 328 patients were analyzed. The culture of 6 (1.1%) and 28 (6.5%)
samples were positive for MRSA and MSSA. The test was not interpretable in 41 (9.3%) patients. The negative
predictive values of the rapid detection test were 99.7% (98.1 to 99.9%) and 99.8% (98.7 to 99.9%) for MSSA and
MRSA, respectively.
Conclusion: The rapid diagnostic test is reliable in excluding the presence of MSSA and MRSA in the samples of
patients with suspected VAP. Its utility should be regarded depending on the prevalence of MRSA.
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Introduction
Because survival is improved in the patients receiving
appropriate empirical antibiotics, guidelines recommend
the coverage of all potential pathogens responsible for an
episode of ventilator-associated pneumonia (VAP) [1,2].
Collection of blood and bronchial specimens precedes
the administration of empirical antibiotics. The choice of
antibiotics is based on the presence of specific risk factors
[2]. After the responsible bacteria in samples were identi-
fied, guidelines recommend reassessing the antibiotic
treatment [2].
Although safe, this strategy exposes the patient to an
overuse of broad-spectrum antibiotics [3]. Overuse of anti-
biotics results in an increase in multidrug resistant patho-
gens, treatment-related side effects and increased cost of
hospitalization. Use of biomarkers, for instance, procalcito-
nin, failed to be effective in septic ICU patients in deciding
whether or not to start antibiotics [4]. The Gram stain of
bronchial sputum is not safe enough to use in deciding
whether or not to start an antimicrobial treatment [5].
With regard to methicillin-resistant Staphylococcus aureus
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(MRSA), this strategy leads to a wide use of vancomycin or
linezolid [6]. These antibiotics are associated with side
effects and increased costs [6].
A rapid detection of resistant bacteria can avoid the use
of unnecessary antibiotics [7]. Because VAP due to MRSA
has been associated with increased mortality [8], the detec-
tion test should have an excellent negative predictive
value. New diagnostic tests using real time polymerase
chain reaction (RT-PCR) detect pathogens in approxi-
mately 60 minutes [9]. They can detect both methicillin-
susceptible Staphylococcus aureus (MSSA) and MRSA in
blood, nasal and surgical site secretions. To date, these
tests have been poorly assessed in bronchial secretions of
patients with suspected VAP.
We hypothesized that the routine use of a rapid detec-
tion (rPCR) test in bronchial secretion samples would
limit the use of anti-MRSA antibiotics. The performance
of the rPCR test has been evaluated on 135 lower respira-
tory tract secretions. However, only the patients with
endotracheal aspirates showing Gram-positive cocci were
included in this study [10]. Using the rPCR tests designed
for nasal secretions and surgical site fluid, our goal was to
assess the technical reliability of the rPCR test for Staphy-
lococcus aureus and its concordance with bronchoalveolar
(BAL) and miniBAL microbiological result.
Materials and methods
The study was conducted in three ICUs from two institu-
tions (Aix Marseille Université and Claude Bernard Uni-
versité Lyon 1). As it was an observational retrospective
study, according to French legislation (articles L.1121-1
paragraph 1 and R1121-2, Public Health Code), neither
informed consent nor approval of the ethics committee
was needed to use data for an epidemiologic study. From
June 2011 to June 2012, the patients were selected if a
VAP episode was suspected [1].
Culture and identification of MRSA
The bronchial secretions were collected using a BAL or a
mini-BAL. Qualitative and quantitative cultures were per-
formed. A quantitative BAL or mini-BAL was defined as
negative if there was less than 104 colony-forming units
(cfu)/mL and 103 cfu/mL of growth from the culture
[11,12].
All respiratory tract samples were divided into two ali-
quots. A first aliquot was inoculated on Columbia 5%
sheep-blood, chocolate PolyViteX and MacConkey agar
media (bioMérieux, Marcy l’Etoile, France). Incubation was
performed at 36°C under 5% CO2 atmosphere for Colum-
bia 5% sheep-blood and chocolate PolyViteX. Growing
microorganisms were identified by using matrix-assisted
laser desorption ionization time-of-flight [13]. Methicillin
resistance was determined for Staphylococcus aureus by
using a disk-diffusion method (Mast Diagnostics, Amiens,
France) after 18 to 24 hours of incubation on Mueller-Hin-
ton agar media (bioMerieux) according with the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) breakpoints.
The second aliquot was used to determine the presence
or not of S. aureus using the rapid detection test. No anti-
biotic active against MRSA was used before a BAL or
mini-BAL was performed. Results were available via the
intranet website of each institution.
rPCR test for S. aureus
Staphylococcus aureus was identified using a rapid diag-
nostic test on a platform Cepheid Xpert real time PCR
assay (Cepheid, Sunnyvale, CA, USA). In the Marseille
study center, an Xpert SA Nasal Complete Kit was used.
In the Lyon study center, an Xpert MRSA/SA SSTI was
used. The extraction, amplification and detection steps
take place in different chambers of a self-contained, sin-
gle-use cartridge containing all reagents required for the
bacterial target detection. Samples were adsorbed onto a
swab, which was inserted in the extraction buffer vial of
the Xpert assay, transferred into the cartridge, and trea-
ted according to the manufacturer’s instructions. Both
the Xpert SA Nasal Complete and the Xpert MRSA/SA
SSTI target the staphylococcal protein A (spa) gene, the
gene for methicillin resistance (mecA) and the staphylo-
coccal cassette chromosome (SCCmec) inserted into the
S. aureus chromosomal attB insertion site, and an inter-
nal-control sample processing control (SPC) three
genetic markers (Bacillus globigii).
The rPCR test was available 24 h a day and 7 days a
week. In Marseille, a microbiologist was responsible for
the procedure in a point-of-care laboratory. In Lyon, a
clinical research assistant performed the rPCR test directly
in the intensive care unit. The detection of a microorgan-
ism is accompanied by a positive signal. This detection is
possible in 58 minutes.
Collection of data
We collected the simplified acute physiology score (SAPS
2) at admission, reason for admission and the duration of
the ICU stay, day of occurrence of the episode of VAP,
result of rPCR test, result of Gram stain and result of
microbiological culture. The analysis was conducted in the
entire cohort and then in the patients with risk factors for
MRSA infection, as defined elsewhere [2].
Economic assessment
The economic assessment conducted examined rPCR test
kit testing as an adjunct for antibiotic management of
VAP empirical treatment in 2013 Euros. Estimates of the
cost of running a rapid detection test are approximately
€45 per test. We considered two approaches to model
antibiotic costs in the empirical treatment of VAP: 1) a
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less expensive option, such as what might be used for
patients without renal failure (€50/day), and 2) a more
expensive option, such as what might be used for patients
with renal impairment (€150/day). The estimate of the
duration of empirical antibiotics (three-days) is derived
from our prior publications [14].
Statistical analysis
A statistical analysis was performed using R-project 2.14 for
GNU Linux Ubuntu. With respect to continuous variables,
data were expressed as median and interquartile range
(25% to 75%). With respect to dichotomous variables, per-
centages were calculated. Regarding MSSA and MRSA,
sensitivity, specificity, positive predictive value, negative
predictive value, positive likelihood and negative likelihood
were computed. In order to assess the efficiency of the
rapid diagnostic test, the Youden index was calculated as
follows: Youden index = (sensitivity + specificity - 1).
A level of P below 0.05 was considered as significant.
Results
Within the study period, 422 samples were analyzed
using the rPCR test in 328 patients. The population con-
sisted of 151 (46%) medical patients, 102 (31%) surgical
patients and 75 (23%) trauma patients. The SAPS 2 was
39 (27 to 52). The duration of ICU stay was 16 (8 to 36)
days. The results of culture were reported as sterile and
commensal flora in 168 (40%) and 70 (16%) cases, respec-
tively. At least one microorganism growth considered as
significant was observed in 184 samples. Pseudomonas
aeruginosa was the most frequently isolated species (n =
45 (11%)). S. aureus was identified in 34 (8.1%) samples,
including 28 (6.5%) MSSA and six (1.4%) MRSA.
All patients with MRSA VAP had significant risk fac-
tors (Table 1). The results of 44 (10.4%) rPCR tests
were given as not interpretable. Forty-one (93%) incon-
clusive tests were reported in Marseille. The technical
characteristics of the rPCR test for MSSA and MRSA
identification are reported in Table 2. The negative pre-
dictive values, that is, the proportion of subjects with a
negative test result who were correctly diagnosed, of the
rPCR test were 99.7% (98.1 to 99.9%) and 99.8% (98.7 to
99.9%) for MSSA and MRSA, respectively. Gram stain
served to identify Gram positive cocci in 94 (22%) sam-
ples. This included 18 (65%) out of 28 positive cultures
for MSSA, and 3 (50%) out of 6 positive cultures for
MRSA. With respect to MRSA, its sensitivity was below
5%. Its specificity was at 99%. Inconclusive tests were
either excluded or included positive tests or negative
tests, respectively.
We identified a specific population of 301 patients
with at least one risk factor for MRSA. Prior duration of
hospitalization (> 5 days), antibiotic treatment in the
preceding 90 days, chronic hemodialysis and central line
or implantable device were found in 257, 131, 11 and
149 patients, respectively. The median number of risk
factors was two (one to three). In those patients, using
only the positive sample for MRSA investigation, the
predictive negative value of the rPCR test for MRSA
detection was 99.7% (98.1 to 99.9%) (Table 2).
Figure 1 reports the cost-effectiveness analysis
depending on the prevalence of MRSA. The cost-effec-
tiveness was based on a strategy including a three-day
empirical antimicrobial therapy. Based on a treatment
cost at €150/day, the rPCR test was cost-effective, inde-
pendent of the prevalence of MRSA. Based on a treat-
ment cost at €50/day, the rPCR test was cost-effective
for MRSA prevalence below 25%.
Discussion
Our study shows that the rPCR test is reliable for the
detection of S. aureus in bronchial secretions of patients
with tracheal intubation. The excellent negative predictive
value suggests that antibiotics directed against MRSA may
not be used in most patients with a negative test. This
finding is in agreement with that published in previous
studies [10,15]. Importantly, the rPCR test cannot confirm
the presence or absence of VAP. The diagnosis of VAP is
based on clinical, radiological and microbiological features.
The striking finding of our study is a prevalence rate
of MRSA below 2%. This prevalence is lower than that
reported in previous studies [14,15]. This is in line with
data regarding the decreased number of bacteremias due
to MRSA in Europe [16]. This low prevalence is a major
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limitation of the present study. Indeed, the predictive
values of a test depend on the prevalence of the event
in the patients being tested. The predictive value of a
negative test decreases as soon as the prevalence of the
event increases. Then, future studies are required to test
the possibility of excluding MRSA in an ICU patient
with a clinical suspicion of VAP using a rPCR test when
the prevalence of MRSA is high.
In routine, Gram stain is the first microbiological result
available for the clinician. Its role remains a matter of
debate. A meta-analysis showed that Gram stain is not
reliable, with the exception of negative findings [17]. Gram
stain may be used to screen the patients at high-risk of
MRSA. In a prior study, the rapid diagnostic test was con-
ducted in endotracheal aspirates showing Gram positive
cocci in clusters [10]. This pre-screening improved the
performance of the rPCR test. However, three out of our
six patients with a positive culture for MRSA had a posi-
tive Gram stain. Thus, this strategy shows that the number
of patients with MRSA is underestimated.
In routine, a diagnostic test should have an excellent
reliability [18]. In our series, the rPCR test was inconclu-
sive in around 10% of the samples. This result differs from
a study showing that all tests were valid [15]. In our study,
this is a limitation of the use of the rPCR test. The test is
not interpretable when the DNA cannot be amplified. In
practice, this is probably related to the features of bron-
chial secretions. The lack of fluidity of samples can pre-
clude their analysis by the device. A pre-treatment aimed
at increasing the sample fluidity may increase the number
of valid tests [15]. Based on local decision, a different
rPCR test was used in each of our two centers. One should
note that most of the inconclusive tests corresponded to
the complete nasal kit. Future studies are required to
Table 2 Technical features of the rapid PCR test









































































































*Including inconclusive tests as positive; Including inconclusive test as negative
Technical characteristics of the rapid PCR test and Gram stain performed on bronchoalveolar lavage samples in all patients and those with at least one risk factor
for methicillin resistant Staphylococcus aureus infection
LR, likelihood ratio; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; NPV, negative predictive value; PPV,
predictive positive value; Se, sensitivity; Sp, specificity
Figure 1 Cost-effectiveness of the rapid detection test for
methicillin-resistant Staphylococcus aureus (MRSA) in the
bronchial samples of patients with suspected ventilator-
associated pneumonia. The x-axis represents the prevalence of
MRSA. The y-axis represents the change in total cost (antimicrobial
therapy and rapid diagnostic test) associated with the use of the
test (in Euros). Cost is based on consecutive use in 100 patients.
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explore whether the SSTI kit results in less technical fail-
ure than the nasal kit.
The cost-effectiveness of the rPCR test is related to the
prevalence of MRSA. The estimated cost of the rapid
diagnostic test is around €45. Using an expensive treat-
ment option, the routine use of the test remains cost-
effective whatever the MRSA prevalence. In contrast,
using a less expensive option, the test seems to be less
cost-effective above 25% MRSA prevalence. Our results
show that risk factors were identified in the six patients
with positive cultures for MRSA. Thus, a careful screen-
ing of patients at high-risk of MRSA carriage improves
the effectiveness of the diagnosis process.
Conclusion
In unselected patients with suspected VAP, the rPCR
test has an excellent negative predictive value. Its rou-
tine use should be discussed according to the prevalence
of MRSA. In our opinion, this test should be used only
in the patients at high-risk of MRSA infection or in
endemic situations.
Key messages
• The prevalence of positive culture for methicillin-
resistant Staphylococcus aureus is less than 2% in
the lower respiratory tract secretions of patients with
suspected ventilator-associated pneumonia.
• The negative predictive value of a rapid diagnostic
test aiming at identifying Staphylococcus aureus in
bronchial secretions is excellent.
• The negative predictive value of a rapid diagnostic
test aiming at identifying methicillin-resistant Staphy-
lococcus aureus in bronchial secretions is excellent.
• The use of a rapid diagnostic test may be asso-
ciated with a reduced use of antibiotics.
• The cost effectiveness of the rapid diagnostic test
should be evaluated according to the prevalence of
methicillin-resistant Stahylococcus aureus.
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